EG25227A - Heterocyclic compounds. - Google Patents

Heterocyclic compounds.

Info

Publication number
EG25227A
EG25227A EG50996A EG50996A EG25227A EG 25227 A EG25227 A EG 25227A EG 50996 A EG50996 A EG 50996A EG 50996 A EG50996 A EG 50996A EG 25227 A EG25227 A EG 25227A
Authority
EG
Egypt
Prior art keywords
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
EG50996A
Other languages
English (en)
Inventor
Robert Hugh Bradbury
Roger John Butlin
Roger James
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26307176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG25227(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9511507.7A external-priority patent/GB9511507D0/en
Priority claimed from GBGB9519666.3A external-priority patent/GB9519666D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of EG25227A publication Critical patent/EG25227A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
EG50996A 1995-06-07 1996-06-06 Heterocyclic compounds. EG25227A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9511507.7A GB9511507D0 (en) 1995-06-07 1995-06-07 Heterocyclic compounds
GBGB9519666.3A GB9519666D0 (en) 1995-09-27 1995-09-27 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
EG25227A true EG25227A (en) 2011-11-17

Family

ID=26307176

Family Applications (1)

Application Number Title Priority Date Filing Date
EG50996A EG25227A (en) 1995-06-07 1996-06-06 Heterocyclic compounds.

Country Status (32)

Country Link
US (3) US5866568A (zh)
EP (1) EP0832082B1 (zh)
JP (1) JP3193058B2 (zh)
KR (1) KR100451523B1 (zh)
CN (1) CN1097051C (zh)
AR (1) AR003132A1 (zh)
AT (1) ATE209200T1 (zh)
AU (1) AU715041B2 (zh)
BR (1) BR9608611A (zh)
CA (1) CA2219742C (zh)
CZ (1) CZ289387B6 (zh)
DE (1) DE69617236T2 (zh)
DK (1) DK0832082T3 (zh)
EG (1) EG25227A (zh)
ES (1) ES2168487T3 (zh)
GE (1) GEP20053470B (zh)
HK (1) HK1005801A1 (zh)
HR (1) HRP960272B1 (zh)
HU (1) HUP9802300A3 (zh)
IL (1) IL122464A (zh)
MX (1) MX9709521A (zh)
MY (1) MY114926A (zh)
NO (1) NO314503B1 (zh)
NZ (1) NZ308619A (zh)
PL (1) PL187897B1 (zh)
PT (1) PT832082E (zh)
RU (1) RU2172738C2 (zh)
SK (1) SK282338B6 (zh)
TR (1) TR199701502T1 (zh)
TW (1) TW340845B (zh)
UA (1) UA58494C2 (zh)
WO (1) WO1996040681A1 (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
JP2001523218A (ja) 1996-02-20 2001-11-20 ブリストル―マイヤーズ・スクイブ・カンパニー ビフェニルイソキサゾール・スルホンアミドの製造法
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
GB9614804D0 (en) * 1996-07-15 1996-09-04 Chiroscience Ltd Resolution process
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
HU227183B1 (en) 1997-04-28 2010-09-28 Encysive Pharmaceuticals Inc Sulfonamide derivatives and pharmaceutical compositions containing them for the treatment of endothelin-mediated disorders
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
HUP0201320A2 (en) 1999-03-19 2002-08-28 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof
US6448239B1 (en) * 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
CA2395684C (en) 1999-12-31 2012-01-03 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
KR100839512B1 (ko) * 2004-07-02 2008-06-19 주식회사 코오롱 설파제를 디아조화체로 하는 산성 항균 염료 및 그를이용한 항균 섬유
WO2006053250A2 (en) 2004-11-12 2006-05-18 Trustees Of Tufts College Lipase inhibitors
US20070054325A1 (en) * 2005-04-14 2007-03-08 Reglia Materials and methods for screening modulators of neural regeneration
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
EP1979001B1 (en) 2005-12-13 2012-04-11 Medimmune Limited Binding proteins specific for insulin-like growth factors and uses thereof
US20100010035A1 (en) * 2006-03-03 2010-01-14 Ramesh Chandra Gupta Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors
BRPI0709950A2 (pt) * 2006-04-13 2011-08-02 Actelion Pharmaceuticals Ltd uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin
BRPI0717106A2 (pt) * 2006-09-21 2013-10-08 Piramal Life Sciences Ltd Compostos para o tratamento de distúrbios metabólicos
CL2008000191A1 (es) 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
US20090155209A1 (en) 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
MX2010003989A (es) * 2007-10-12 2010-04-27 Astrazeneca Ab Composicion zibotentan que contiene mannitol y/o celulosa microcristalina.
HUE039416T2 (hu) 2008-06-19 2018-12-28 Takeda Pharmaceuticals Co Heterociklusos vegyület és ennek alkalmazása
KR101677778B1 (ko) * 2009-02-06 2016-11-18 니뽄 신야쿠 가부시키가이샤 아미노피라진 유도체 및 의약
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
US20230227477A1 (en) * 2020-06-25 2023-07-20 Wake Forest University Health Sciences Compounds for sensing reactive oxygen species and methods for using the same
JP2023541766A (ja) 2020-07-10 2023-10-04 アストラゼネカ・アクチエボラーグ 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ
TW202317555A (zh) 2021-06-22 2023-05-01 日商亞克醫藥股份有限公司 化合物、內皮素a受體拮抗劑及醫藥組合物
US20240058331A1 (en) 2022-08-12 2024-02-22 Astrazeneca Ab Combination therapies for treatment of cirrhosis with portal hypertension

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0655708B2 (ja) * 1985-05-13 1994-07-27 三井東圧化学株式会社 スルホンアミド系化合物及び農業用殺菌剤
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
WO1990009787A1 (en) * 1989-02-27 1990-09-07 The Du Pont Merck Pharmaceutical Company Novel sulfonamides as radiosensitizers
TW270116B (zh) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (zh) * 1992-02-24 1994-06-01 Squibb & Sons Inc
CA2133090A1 (en) * 1992-04-22 1993-10-28 Wayne L. Cody Endothelin antagonists ii
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
EP0650484B1 (en) * 1992-07-17 2000-01-26 Smithkline Beecham Corporation Endothelin receptor antagonists
TW287160B (zh) * 1992-12-10 1996-10-01 Hoffmann La Roche
FI941826A (fi) * 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
DE4426346A1 (de) * 1994-07-25 1996-02-01 Basf Ag Herbizide Pyrazinderivate
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB2295616A (en) * 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
KR100359396B1 (ko) * 1995-04-04 2003-03-15 텍사스 바이오테크놀로지 코포레이션 엔도텔린의활성을조절하는티에닐-,푸릴-및피롤릴설폰아미드및이의유도체

Also Published As

Publication number Publication date
CZ388797A3 (cs) 1998-03-18
MX9709521A (es) 1998-03-31
NZ308619A (en) 2000-01-28
CA2219742A1 (en) 1996-12-19
DE69617236T2 (de) 2002-07-11
WO1996040681A1 (en) 1996-12-19
CN1097051C (zh) 2002-12-25
TR199701502T1 (xx) 1998-03-21
HRP960272B1 (en) 2006-06-30
HUP9802300A3 (en) 2002-02-28
CA2219742C (en) 2007-01-16
KR19990022327A (ko) 1999-03-25
IL122464A (en) 2002-05-23
ATE209200T1 (de) 2001-12-15
JP3193058B2 (ja) 2001-07-30
MY114926A (en) 2003-02-28
DE69617236D1 (de) 2002-01-03
NO975700L (no) 1997-12-05
PL187897B1 (pl) 2004-10-29
IL122464A0 (en) 1998-09-15
NO314503B1 (no) 2003-03-31
JPH11509175A (ja) 1999-08-17
RU2172738C2 (ru) 2001-08-27
SK168097A3 (en) 1998-05-06
UA58494C2 (uk) 2003-08-15
HUP9802300A2 (hu) 1999-10-28
KR100451523B1 (ko) 2004-12-03
EP0832082A1 (en) 1998-04-01
US6258817B1 (en) 2001-07-10
AU715041B2 (en) 2000-01-13
CN1192739A (zh) 1998-09-09
TW340845B (en) 1998-09-21
NO975700D0 (no) 1997-12-05
CZ289387B6 (cs) 2002-01-16
PL324660A1 (en) 1998-06-08
AU5840396A (en) 1996-12-30
AR003132A1 (es) 1998-07-08
BR9608611A (pt) 1999-05-11
HRP960272A2 (en) 1997-08-31
DK0832082T3 (da) 2002-05-21
US5866568A (en) 1999-02-02
ES2168487T3 (es) 2002-06-16
GEP20053470B (en) 2005-02-25
SK282338B6 (sk) 2002-01-07
PT832082E (pt) 2002-04-29
US6060475A (en) 2000-05-09
EP0832082B1 (en) 2001-11-21
HK1005801A1 (en) 1999-01-29

Similar Documents

Publication Publication Date Title
EG25227A (en) Heterocyclic compounds.
ZA965935B (en) Heterocyclic compounds.
EG24195A (en) Heterocyclic compounds
ZA9610020B (en) Heterocyclic compounds
ZA97912B (en) Heterocyclic compounds.
GB9512697D0 (en) Heterocyclic compounds
ZA961444B (en) Pyrazolylbenzoyl derivatives.
GB9518552D0 (en) New heterocyclic compounds
ZA965505B (en) Novel compounds.
PL322722A1 (en) Novel heterocyclic compounds
ZA961449B (en) Isoxazolylbenzoyl derivatives.
GB9504361D0 (en) Heterocyclic compounds
ZA969973B (en) 2-thioxo-imidazolidin-4-one derivatives.
ZA979617B (en) Novel heterocyclic compounds.
ZA967741B (en) Diarylalkenylamine derivatives.
ZA962821B (en) 4-indolylpiperazinyl derivatives.
ZA964560B (en) Anit-viral compounds.
ZA967357B (en) Pyrazol-4-ylbenzoyl derivatives.
PL325637A1 (en) Novel heterocyclic compounds
ZA964034B (en) N-aminopyridone derivatives.
AU1542295A (en) Heterocyclic compounds
ZA962734B (en) Heterocyclic compounds
ZA969560B (en) Substituted 1-methyl-3-phenylpyrazoles.
ZA967934B (en) Heterocyclic compounds.
ZA966126B (en) Heterocyclic compounds.